Deferoxamine pharmacokinetics
References (15)
- et al.
Quantification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and simultaneous ultraviolet-visible/radioactive detection
Anal Biochem
(1992) - et al.
Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis
Br J Clin Pharmacol
(1987) - et al.
Ocular changes in patients undergoing long-term desferrioxamine treatment
Br J Opthalmol
(1984) - et al.
Unbound iron binding capacity: Correlation with non-transferrin bound plasma iron and deferoxamine levels
- et al.
Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemia patients
Drugs Metab Disp
(1993) - et al.
Intensive iron-chelation with desferrioxamine in iron-loading anaemias
Clin Sci Mol Med
(1978) - et al.
Subcutaneous depot desferrioxamine (CGH 749B): Relationship of pharmacokinetics to efficacy and drug metabolism
Blood
(1997)
Cited by (60)
Vascularized 3D printed scaffolds for promoting bone regeneration
2019, BiomaterialsNeuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response
2019, BiomaterialsCitation Excerpt :Although DFX most likely sequestered excess available free iron and did upregulate the antioxidant activity at the earliest time-point, it was not able to decrease the overall activation of ROS producing species by 7-day. This may have been due to an abundance of reactive oxygen and nitrogen species at later time-points as well as unavailability of DFX due to its short half-life (∼6-h) [76], which may warrant a larger, more frequent administration of the drug. Significant evidence demonstrates the profound activation and recruitment of immune cells to the injury site following intracortical electrode at acute [147] and chronic time-points [117,148].
A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
2018, Blood ReviewsCitation Excerpt :Evidence suggests that the short-term clinical effectiveness of all three iron chelators is similar [73], although efficacy in different organs may vary [74,75]. Deferoxamine, the first commercially available iron chelator, is administered by parenteral infusion for 8–12 hours, 5–7 nights per week [67,71,76]. The benefits of deferoxamine are well documented [63,64], but the demanding treatment regimen can lead to poor adherence [1,77].
Contemporary approaches to treatment of beta-thalassemia intermedia
2012, Blood ReviewsDesign and synthesis of fluorine-substituted 3-hydroxypyridin-4-ones
2010, Tetrahedron LettersCirculating Iron in Patients with Sickle Cell Disease Mediates the Release of Neutrophil Extracellular Traps
2023, Transfusion Medicine and Hemotherapy